Today
Stokes is half-right about mental health and workers’ comp rorts
Disability insurers do not need government intervention. They need to change products for new customers that tighten eligibility.
This Month
A GST on health insurance would be the tipping point for members
A 10 per cent increase in premiums would be a self-defeating policy that would hurt households, destabilise the health system, and increase pressure on public hospitals.
Childbirth medtech eyes US market with $30m raise
Perth-based VitalTrace has tapped Acova Capital to raise funds for its commercialisation push.
GenesisCare US cancer clinic sale to TPG ends painful chapter
Owner Oaktree Capital is selling the Australian company’s Florida and North Carolina clinics for a fraction of their former value.
Drug giants targeting Australia’s PBS are paying tiny amounts of tax
Global pharmaceutical giants make billions of dollars in Australia but pay a fraction of that in tax. They say the price they get for their drugs is too low.
‘Not for everybody’: MDMA production for PTSD begins in Australia
Under tight security, an Australian facility has manufactured 10,000 capsules of the psychedelic drug for the first time.
Ramsay to close psychology clinics in blow for mental health patients
The nation’s largest private hospital operator says 17 of its 20 psychology clinics will close by September.
Why clinical labs are hot property for asset managers
Wentworth Capital is eyeing a further $600 million in life science property investments with BlackRock.
Telix subpoenaed by US regulator over cancer therapy
The Melbourne-based biotech says it has notified ASIC about the investigation by US regulators.
How an introvert’s brand raked in $8m in sales
Hayden Brass knew his humble family business could be more. Now the founder of health and wellness company Zea is a 2025 BOSS Young Executive.
Jefferies, Mayne Pharma in spotlight after suitor’s court win
US medicines giant Cosette has successfully sought confidential modelling that it says could prove it was given incomplete financial information.
Mesoblast shares soar 35pc on strong cell therapy sales data
The biotech says sales of its first commercial therapy, Ryoncil, were $20 million in the quarter ending June 30.
Armitage readies healthtech for sale, tapping Houlihan Lokey
Mark De Ambrosis’ Armitage first bought into MYP in December 2020, acquiring a stake just north of 50 per cent.
Waiting to get rich from biotech? Don’t hold your breath
Regulatory upheaval in the US and a venture capital drought are dampening investor appetites, but there are still diamonds in the rough.
The 10 wealthiest executives in the ASX 300 revealed
Healthcare and tech company bosses, including the co-founders of the ASX’s newest $30 billion company Pro Medicus, dominate the Rich Bosses list.
Healthscope’s not-for-profit plan to bid for itself
Healthscope’s lenders are weighing up a proposal to restructure the hospital operator into a not-for-profit company which will save $100 million on payroll tax.
AI is giving private equity a new headache
The local boss of US private equity group Riverside Company says a kid can use AI to replicate a company’s software in hours. That’s a big new risk to price in.
New tech deal alert: General Atlantic hires advisers to sell $1b Mable
Mable, a marketplace platform that works with NDIS participants and at-home carers, was founded in 2014 by Peter Scutt and Tony Charara.
Stop the mental health blowout, says Labor MP
Paediatrician and MP Mike Freelander says the way society diagnoses mental health is part of the problem behind a huge rise in compensation claims.
CSL prepares to slash R&D as it grapples with looming Trump tariffs
The market is focused on a mooted 200 per cent levy on the pharmaceutical giant’s goods. There are far more significant changes afoot at the company.